NLRP3 and bronchopulmonary dysplasia: 18β-Glycyrrhetinic acid (18β-GA) inhibited the activation of NLRP3 inflammasome and NLRP3-related pyroptosis, decreased ROS level and pulmonary inflammation, improved alveolar development of BPD rats (Qing et al., 2022).